San Diego-based Ambrx has expanded its Series C round, announcing today that it has raised an additional $3M in venture funding. Financing came from the Scottish Widows Investment Partnership. The additional capital brings the firm's Series C round of funding to $55M. Ambrx said that the new funding will be used to further expand its novel protein modification platform, support the development of its product pipeline, and for general working capital purposes. More information »